Reformbiologics

Reformbiologics

Technology platform transforming biotherapeutic formulations to extend product life cycles, enable alternative dosing, and improve manufacturing efficiency.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor

€0.0

round
*
N/A

$4.1m

Post IPO Equity
Total Funding000k
Notes (0)
More about Reformbiologics
Made with AI
Edit

ReForm Biologics operates in the biopharmaceutical industry, focusing on the formulation of biotherapeutics to enhance patient outcomes. The company has developed a proprietary technology platform that transforms the formulation of protein-based therapeutics. This platform extends product life cycles, enables alternative dosing methods, and improves manufacturing efficiency, thereby providing significant value to its biopharmaceutical partners. ReForm Biologics collaborates with drug companies through formulation development partnerships and product-specific licenses. The business model revolves around these collaborations and licensing agreements, which generate revenue by offering innovative solutions to improve the efficacy and delivery of biotherapeutics. The primary clients are biopharmaceutical companies looking to optimize their therapeutic products and manufacturing processes.

Keywords: biotherapeutics, technology platform, formulation development, protein therapeutics, product life cycles, alternative dosing, manufacturing efficiency, biopharmaceutical partners, licensing, patient outcomes.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo